GlassScriptPhysician profile
Shobana Sivan
NPI 1922365485
$1,001.23
in general payments reported to CMS, 2019-2025
19 companies · $783 in 2025
The $783 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $218 · 2025: $783.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $958 · Education: $43.63.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $957.60 |
| Education | $43.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $142.23 | 2024-2025 | Tarpeyo |
| Merck Sharp & Dohme LLC | $118.39 | 2025 | Prevymis |
| Otsuka America Pharmaceutical, INC. | $103.18 | 2024-2025 | Jynarque, Voyxact |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.52 | 2025 | Jardiance |
| Xeris Pharmaceuticals, INC. | $68.56 | 2025 | Keveyis |
| Travere Therapeutics, INC. | $63.56 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $56.07 | 2024-2025 | Farxiga |
| Alexion Pharmaceuticals, INC. | $44.86 | 2025 | Ultomiris |
| Opko Pharmaceuticals, LLC | $43.63 | 2024 | Rayaldee |
| Novartis Pharmaceuticals Corporation | $42.43 | 2025 | |
| Aurinia Pharma U.S., INC. | $38.77 | 2024-2025 | Lupkynis |
| Vantive US Healthcare LLC | $30.64 | 2025 | Renal - Acute |
| Cycle Pharmaceuticals INC | $27.42 | 2025 | Ormalvi |
| Mallinckrodt Hospital Products INC. | $26.97 | 2025 | Terlivaz |
| Ani Pharmaceuticals, INC. | $24.97 | 2024 | Purified Cortrophin Gel |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $23.80 | 2024 | Vafseo |
| Ardelyx, INC. | $22.76 | 2025 | Ibsrela |
| Lilly USA, LLC | $19.82 | 2025 | Jardiance |
| Amgen INC. | $17.65 | 2024 | Repatha, Otezla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shobana Sivan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.